Core Insights - XL-protein GmbH has entered into a worldwide License, Development and Commercialization Agreement with Grifols for a novel long-acting biopharmaceutical product [1] - The collaboration will utilize XL-protein's PASylation® technology to enhance the circulation and effectiveness of Grifols' therapeutics [2] - Financial terms include an upfront payment, milestone payments, and tiered royalties on sales from marketed therapeutics, with Grifols holding exclusive marketing rights [3] Company Overview - Grifols is a global healthcare company founded in 1909, specializing in plasma-derived medicines and innovative healthcare solutions across more than 110 countries [6] - XL-protein is a privately owned biotech company based in Germany, focusing on developing biologics with extended half-life and enhanced in vivo activity through its PASylation® technology [6]